Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149589 | 0.86 | L3MBTL1 (0.57) | L3MBTL1EPHX2PPARACTSSTDP1 | |
| SCHEMBL26647630 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1MEN1KMT2AMMP3 | |
| SCHEMBL22367540 | 0.83 | L3MBTL1 (0.55) | L3MBTL1MMP3MMP9MMP8EPHX2 | |
| SCHEMBL3421550 | 0.82 | ALDH1A1 (0.47) | L3MBTL1MEN1KMT2ALMNATDP1 | |
| SCHEMBL26994876 | 0.82 | RECQL (0.54) | SMN1; SMN2TAAR1MEN1KMT2AMMP3 | |
| SCHEMBL21074172 | 0.81 | ALDH1A1 (0.42) | L3MBTL1MEN1KMT2APPARATDP1 | |
| SCHEMBL18686234 | 0.81 | SYK (0.52) | L3MBTL1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL26696140 | 0.80 | GAA (0.47) | L3MBTL1EPHX2 | |
| SCHEMBL7056898 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MMP3MMP9MMP8LMNA | |
| SCHEMBL18668976 | 0.79 | KMT2A (0.51) | L3MBTL1MEN1KMT2ALMNAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | L3MBTL1 2681/4885SMN1; SMN2 700/4885TAAR1 3590/4885 |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | L3MBTL1 2681/4885SMN1; SMN2 700/4885TAAR1 3590/4885 |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | L3MBTL1 3004/4885SMN1; SMN2 1038/4885TAAR1 3767/4885 |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | L3MBTL1 2681/4885SMN1; SMN2 700/4885TAAR1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.